Heart Failure
📧 Sign up to get email alerts when something new happens for Heart Failure.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2019-09-20FDA Approved: VALSARTAN — Supplemental Application (Amneal Pharmaceuticals LLC)
FDA approves a supplemental application for VALSARTAN by Amneal Pharmaceuticals LLC (ANDA 204011) to support the generic product.
-
CLINICAL_TRIALS trial_result · 2019-09-19Clinical Trial Update: Study to Assess the Safety of BAY1067197 in Stable Heart Failure Patients on Standard Therapy Including ß-blocker [Phase 2]
Phase 2 clinical trial assessing the safety of BAY1067197 in stable heart failure patients on standard therapy including a beta-blocker has …
-
CLINICAL_TRIALS trial_result · 2019-09-16Clinical Trial Update: Chronicle Offers Management to Patients With Advanced Signs and Symptoms of Heart Failure (COMPASS-HF) [NA]
Clinical trial update for COMPASS-HF (NCT00643279) related to management for patients with advanced signs and symptoms of heart failure; res…
-
FDA approval · 2019-09-13FDA Approved: VALSARTAN — Supplemental Application (Alembic Pharmaceuticals Limited)
The FDA approved a supplemental application for valsartan from Alembic Pharmaceuticals Limited (ANDA 091367).
-
CLINICAL_TRIALS trial_result · 2019-09-09Clinical Trial Update: "Hub and Satellite" Heart Failure Provider's Network Study [NA]
Completed clinical trial evaluating a hub-and-satellite network for heart failure management; results posted in 2019.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2019-09-09Clinical Trial Update: Clinical Evaluation of HW005 Ventricular Assist System for the Treatment of Advanced Heart Failure in Japan [NA]
Clinical trial update for HW005 Ventricular Assist System in Japan has completed; results posted in 2019.
-
FDA approval · 2019-09-06FDA Approved: ETHACRYNIC ACID — Original Application (Lupin Pharmaceuticals, Inc.)
FDA approved Lupin Pharmaceuticals, Inc.'s Original Application for Ethacrynic acid, authorizing a generic version of the loop diuretic. Thi…
-
CLINICAL_TRIALS trial_result · 2019-09-06Clinical Trial Update: How to Prevent Heart Failure Readmission by Using Lung Impedance Device (HOPE-HF Study) [Phase 3]
A Phase 3 clinical trial update investigates preventing heart failure readmissions using a lung impedance device (HOPE-HF study).
-
FDA approval · 2019-09-04FDA Approved: VALSARTAN — Supplemental Application (Macleods Pharmaceuticals Limited)
The FDA approved a supplemental application for VALSARTAN submitted by Macleods Pharmaceuticals Limited, indicating approval of changes to t…
-
FDA approval · 2019-09-03FDA Approved: VALSARTAN — Supplemental Application (Lupin Pharmaceuticals, Inc.)
FDA approved Lupin Pharmaceuticals' supplemental application for valsartan, a generic angiotensin II receptor blocker, for approved labeling…
-
FDA approval · 2019-09-03FDA Approved: VALSARTAN — Supplemental Application (SQUARE PHARMACEUTICALS LIMITED)
FDA approved a supplemental application for valsartan submitted by Square Pharmaceuticals Limited. This approval pertains to the generic pro…
-
CLINICAL_TRIALS trial_result · 2019-08-28Clinical Trial Update: A Dose Finding Study to Assess the Effect of LIK066 Compared to Placebo or Empagliflozin in Patients With Type 2 Diabetes Mellitus and Heart Failure [Phase 2]
A Phase 2 dose-finding trial evaluating LIK066 versus placebo or empagliflozin in patients with type 2 diabetes mellitus and heart failure h…
-
FDA approval · 2019-08-27FDA Approved: ETHACRYNIC ACID — Original Application (ScieGen Pharmaceuticals Inc)
FDA approved Ethacrynic acid from ScieGen Pharmaceuticals Inc under an Original Application (ANDA211232).
-
CLINICAL_TRIALS trial_result · 2019-08-21Clinical Trial Update: Spironolactone in Adult Congenital Heart Disease [Phase 2]
Phase 2 trial update for spironolactone in adults with congenital heart disease and heart failure, with results posted.
-
FDA approval · 2019-08-20FDA Approved: VALSARTAN — Supplemental Application (Unichem Pharmaceuticals (USA), Inc.)
The FDA approved a supplemental application for VALSARTAN submitted by Unichem Pharmaceuticals (USA), Inc.
-
CLINICAL_TRIALS trial_result · 2019-08-20Clinical Trial Update: Safety and Efficacy of Early, seQUential Oral dIuretic Nephron blockAde In Acute Heart Failure [Phase 4]
A Phase 4 clinical trial update evaluating the safety and efficacy of Early, sequential Oral Diuretic Nephron blockade in Acute Heart Failur…
-
CLINICAL_TRIALS trial_result · 2019-08-16Clinical Trial Update: Peritoneal Dialysis in Congestive Heart Failure [Phase 3]
Phase 3 clinical trial on peritoneal dialysis for congestive heart failure was terminated.
-
CLINICAL_TRIALS trial_result · 2019-08-14Clinical Trial Update: Exercise and Cognitive Retraining to Improve Cognition in Heart Failure. [NA]
Clinical trial evaluating exercise and cognitive retraining to improve cognition in heart failure has completed with results posted in 2019.
-
CLINICAL_TRIALS trial_result · 2019-08-12Clinical Trial Update: QuickFlex Micro Left Ventricular Lead Post Approval Study
Post-approval study update for the QuickFlex Micro Left Ventricular Lead in heart failure patients; study completed with results posted in 2…
-
CLINICAL_TRIALS research · 2019-08-12Clinical Trial Update: Advance Cardiac Resynchronization Therapy (CRT) Registry
Clinical trial update for the Advance Cardiac Resynchronization Therapy (CRT) Registry, completed with results posted in 2019.
-
FDA approval · 2019-08-07FDA Approved: ENALAPRIL MALEATE — Supplemental Application (Taro Pharmaceuticals U.S.A., Inc.)
FDA approves a supplemental application for enalapril maleate by Taro Pharmaceuticals U.S.A., Inc., pertaining to an approved product (gener…
-
FDA approval · 2019-08-06FDA Approved: CHLORTHALIDONE — Original Application (Unichem Pharmaceuticals (USA), Inc.)
FDA approved the original application for chlorthalidone from Unichem Pharmaceuticals (USA), Inc., enabling a generic version of the diureti…
-
CLINICAL_TRIALS trial_result · 2019-08-06Clinical Trial Update: Effect of Doxycycline on Cardiac Remodelling in STEMI Patients [Phase 3]
Phase 3 clinical trial investigating the effect of doxycycline on cardiac remodeling in patients with STEMI and anterior wall myocardial inf…
-
FDA approval · 2019-08-05FDA Approved: SPIRONOLACTONE — Supplemental Application (Amneal Pharmaceuticals LLC)
FDA approved Amneal Pharmaceuticals LLC's supplemental application for spironolactone, enabling the marketing of a new generic product.
-
CLINICAL_TRIALS trial_result · 2019-08-02Clinical Trial Update: Efficacy, Safety and Tolerability of Sexelaxin When Added to Standard Therapy in AHF [Phase 3]
Phase 3 trial of Sexelaxin added to standard therapy in acute heart failure was terminated; results posted in 2019.